Mercer Global Advisors Inc. ADV Has $4.02 Million Stock Holdings in Genmab A/S (NASDAQ:GMAB)

Mercer Global Advisors Inc. ADV lessened its holdings in Genmab A/S (NASDAQ:GMABGet Rating) by 11.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 101,508 shares of the company’s stock after selling 12,733 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Genmab A/S were worth $4,016,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of GMAB. Greenleaf Trust boosted its holdings in shares of Genmab A/S by 2.4% during the 3rd quarter. Greenleaf Trust now owns 10,150 shares of the company’s stock valued at $444,000 after acquiring an additional 240 shares in the last quarter. Cordasco Financial Network boosted its holdings in shares of Genmab A/S by 40.8% during the 3rd quarter. Cordasco Financial Network now owns 915 shares of the company’s stock valued at $40,000 after acquiring an additional 265 shares in the last quarter. Captrust Financial Advisors boosted its holdings in shares of Genmab A/S by 23.2% during the 3rd quarter. Captrust Financial Advisors now owns 1,414 shares of the company’s stock valued at $62,000 after acquiring an additional 266 shares in the last quarter. Mark Sheptoff Financial Planning LLC boosted its holdings in shares of Genmab A/S by 16.7% during the 3rd quarter. Mark Sheptoff Financial Planning LLC now owns 2,100 shares of the company’s stock valued at $92,000 after acquiring an additional 300 shares in the last quarter. Finally, Marotta Asset Management boosted its holdings in shares of Genmab A/S by 2.1% during the 4th quarter. Marotta Asset Management now owns 17,415 shares of the company’s stock valued at $689,000 after acquiring an additional 359 shares in the last quarter. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts recently issued reports on the company. Guggenheim lowered Genmab A/S from a “buy” rating to a “neutral” rating in a research report on Monday, January 3rd. Morgan Stanley lowered their target price on Genmab A/S from $33.00 to $30.00 and set an “underweight” rating for the company in a research report on Tuesday, April 12th. JPMorgan Chase & Co. lowered their target price on Genmab A/S from 3,200.00 to 3,100.00 in a research report on Friday, February 25th. UBS Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, March 16th. Finally, SVB Leerink lowered their target price on Genmab A/S from $42.00 to $39.00 and set a “market perform” rating for the company in a research report on Thursday, February 17th. Four investment analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $480.86.

Shares of GMAB stock traded up $1.60 during mid-day trading on Tuesday, hitting $38.03. The company’s stock had a trading volume of 17,872 shares, compared to its average volume of 631,318. Genmab A/S has a 52 week low of $30.08 and a 52 week high of $49.07. The company has a market cap of $25.00 billion, a PE ratio of 49.90, a P/E/G ratio of 1.67 and a beta of 1.04. The company’s fifty day simple moving average is $34.59 and its 200-day simple moving average is $37.89.

Genmab A/S (NASDAQ:GMABGet Rating) last issued its earnings results on Wednesday, February 16th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. Genmab A/S had a return on equity of 14.23% and a net margin of 35.58%. The business had revenue of $402.74 million during the quarter, compared to analyst estimates of $387.16 million. On average, equities analysts forecast that Genmab A/S will post 0.78 EPS for the current year.

Genmab A/S Company Profile (Get Rating)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Further Reading

Institutional Ownership by Quarter for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.